PellePharm

PellePharm, Inc. was founded in 2012 and is headquartered in California, USA. It is a biopharmaceutical company dedicated to developing new therapies for rare skin diseases. Its main research areas currently include Gorlin Syndrome and high-frequency basal cell carcinoma (BCC), which are characterized by the ability to cut off tumor genetic pathways at the source.